MIDN Knockout Cell Line (A549)

The choice depends on whether you are studying MIDN (midnolin)'s role as the recently characterized ubiquitin-independent proteasome adapter that delivers immediate-early gene (IEG) transcription factors for degradation or its emerging roles in cancer biology. The Knockout line is the standard tool for asking whether midnolin is required for the ubiquitin-independent degradation of nuclear transcription factors — Gu et al. (Science 2023) demonstrated that midnolin uses its Catch domain to bind unstructured regions in substrates (forming β strands), associates with the proteasome via an α-helix, and uses a ubiquitin-like domain to promote substrate destruction, targeting IEG products including c-Fos, FosB, EGR1, IRF4, and NeuroD1 for ubiquitination-independent proteasomal degradation. Overexpression is useful for studying midnolin-induced IEG protein clearance. For protein homeostasis and cancer biology research, the EDITGENE MIDN Knockout in A-549 is highly informative — midnolin loss stabilizes IEG products (c-Fos, EGR1, FosB), enabling study of IEG-driven processes in lung cancer context. Rescue with wild-type, Catch-domain-mutant, or Ubl-domain-mutant midnolin enables structure-function studies of this newly characterized degradation pathway. The knockout is valuable for studying B cell lymphoma and MYC-driven B cell leukemia where midnolin has emerged as an essential factor — MIDN deletion suppresses MYC-driven B cell malignancy growth, making it a potential cancer target. The midnolin-proteasome pathway represents a paradigm shift in protein degradation biology.

Primary applications: • IEG transcription factor stability: c-Fos, FosB, EGR1, IRF4, NeuroD1 protein levels and half-life analysis following stimulation (growth factors, serum, depolarization) to characterize midnolin-dependent degradation. • Ubiquitin-independent proteasomal degradation: cycloheximide chase or pulse-chase studies of MIDN substrates in the absence/presence of proteasome inhibitors and ubiquitination inhibitors. • B cell lymphoma biology: MYC-driven B cell leukemia/myeloma cell growth and viability — MIDN loss has been shown to suppress MYC-driven B cell malignancy growth. • Midnolin pathway substrate discovery: proteomics in MIDN-null versus rescued cells to identify additional midnolin substrates beyond the characterized IEG products. EDITGENE recommends this model for researchers investigating the recently characterized ubiquitin-independent midnolin-proteasome pathway, IEG protein turnover, and emerging midnolin-targeted cancer therapeutic strategies in MYC-driven malignancies.

Yes. MIDN rescue experiments require attention to the three functional domains: • Construct design: use a codon-modified MIDN sequence with a small C-terminal tag (FLAG, HA). MIDN has N-terminal ubiquitin-like (Ubl) domain, central 'Catch' domain (binds unstructured substrate regions), and C-terminal α-helical proteasome-binding region — preserve all elements (the CUHC architecture). • Catch-domain-mutant rescue: hydrophobic residue mutations in the Catch domain disrupt substrate binding without affecting proteasome association — the standard specificity control for substrate delivery functions. • Ubl-domain-mutant rescue: ubiquitin-like domain mutations disrupt substrate destruction without affecting catch/recognition. • Proteasome-binding-deficient rescue: α-helical domain mutations disrupt proteasome association, generating MIDN that catches substrates but cannot deliver them for degradation. • Functional readout: rescue should restore IEG transcription factor (c-Fos, EGR1, FosB) degradation kinetics measured by cycloheximide chase or pulse-chase analysis. A-549 transduces efficiently with lentivirus and supports systematic structure-function rescue experiments of this newly characterized degradation pathway.